Involvement of UDP-glucuronosyltransferases in the extensive liver and intestinal first-pass metabolism of flavonoid baicalein

Pharmaceutical Research

Volumn 24, Issue 1, 2007, Pages 81-89

  Zhang, Li ^a   Lin, Ge ^a   Zuo, Zhong ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Baicalein; Baicalin; Glucuronidation; Sulfation; UDP glucuronosyltransferase

Indexed keywords

BAICALEIN; BAICALEIN 7 O GLUCURONIDE; BAICALEIN SULFATE; CYTOCHROME P450; DRUG METABOLITE; FLAVONOID; GLUCURONOSYLTRANSFERASE; ISOENZYME;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME KINETICS; FIRST PASS EFFECT; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTESTINE ABSORPTION; LIVER METABOLISM; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; RAT; SULFONATION;

ALGORITHMS; ANIMALS; ANTIOXIDANTS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; FLAVANONES; GLUCURONOSYLTRANSFERASE; HUMANS; HYDROXYLATION; INTESTINES; ISOENZYMES; LIVER; MICROSOMES; MICROSOMES, LIVER; RATS; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFATES;

EID: 33845424456     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9126-y     Document Type: Article

References (25)

1. C. S. Yang, J. M. Landau, M. T. Huang, and H. L. Newmark. Inhibition of carcinogenesis by dietary polyphenolic compounds Ann. Rev. Nutr. 21:381-406 (2001).
2. M. G. Hertog, P. C. Hollman, M. B. Katan, and D. Kromhout. Intake of potentially anticarcinogenic flavonoids and their determinant in adults in the Netherlands Nutr. Cancer 20:21-29 (1993).
3. P. A. Kroon, M. N. Clifford, A. Crozier, A. J. Day, J. L. Donovan, C. Manach, and G. Williamson. How should we assess the effects of exposure to dietary polyphenols in vitro? Am. J. Clin. Nutr. 80:15-21 (2004).
4. C. Manach and J. L. Donovan. Pharmacokinetics and metabolism of dietary flavonoids in humans Free Radical Res. 38:771-785 (2004).
5. T. Hong, G. B. Jin, S. Cho, and J. C. Cyong. Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice Planta Med. 68:268-271 (2002).
6. M. Kimata, M. Shichijo, T. Miura, I. Serizawa, N. Inagaki, and H. Nagai. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells Clin. Exp. Allergy 30:501-508 (2000).
7. Z. H. Shao, T. L. Vanden Hoek, Y. Qin, L. B. Becker, P. T. Schumacker, C. Q. Li, L. Dey, E. Barth, H. Halpern, G. M. Rosen, and C. S. Yuan. Baicalein attenuates oxidant stress in cardiomyocytes Am. J. Physiol. 282:H999-H1006 (2002).
8. T. Akao, K. Kawabata, E. Yanagisawa, K. Ishihara, Y. Mizuhara, Y. Wakui, Y. Sakashita, and K. Kobashi. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form J. Pharm. Pharmacol. 52:1563-1568 (2000).
9. M. Y. Lai, S. L. Hsiu, S. Y. Tsai, Y. C. Hou, and P. D. Chao. Comparison of metabolic pharmacokineties of baicalin and baicalein in rats J. Pharm. Pharmacol. 55:205-209 (2003).
10. L. Zhang, G. Lin, Q. Chang, and Z. Zuo. Role of intestinal first-pass metabolism of baicalein in its absorption process Pharm. Res. 22:1050-1058 (2005).
11. Y. Otake, F. Hsieh, and T. Walle. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes Drug Metab. Dispos. 30:576-581 (2002).
12. M. G. Boersma, H.van der Woude, J. Bogaards, S. Boeren, J. Vervoort, N. H. Cnubben, M. L.van Iersel, P. J.van Bladeren, and I. M. Rietjens. Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases Chem. Res. Toxicol. 15:662-670 (2002).
13. M. D. Green, C. D. King, B. Mojarrabi, P. I. Mackenzie, and T. R. Tephly. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3 Drug Metab. Dispos. 26:507-512 (1998).
14. E. J. Oliveira and D. G. Watson. In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes FEBS Lett. 471:1-6 (2000).
15. N. K. Basu, M. Ciotti, M. S. Hwang, L. Kole, P. S. Mitra, J. W. Cho, and I. S. Owens. Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake J. Biol. Chem. 279:1429-1441 (2004).
16. M. G. Soars, R. J. Riley, K. A. Findlay, M. J. Coffey, and B. Burchell. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney Drug Metab. Dispos. 29:121-126 (2001).
17. R. H. Tukey and C. P. Strassburg. Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease Ann. Rev. Pharmacol. 40:581-616 (2000).
18. M. B. Fisher, M. F. Paine, T. J. Strelevitz, and S. A. Wrighton. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism Drug Metab. Rev. 33:273-297 (2001).
19. J. O. Miners, K. M. Knights, J. B. Houston, and P. I. Mackenzie. In vitro-in vito correlations for drugs and other compounds eliminated by glucuronidation in humans: Pitfalls and promises Biochem. Pharmacol. 71:1531-1539 (2006).
20. T. S. Tracy. Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions Curr. Drug Metab. 4:341-346 (2003).
21. A. J. Day, Y. Bao, M. R. Morgan, and G. Williamson. Conjugation position of quercetin glucuronides and effect on biological activity Free Radic. Bio. Med. 29:1234-1243 (2000).
22. L. Zhang, G. Lin, Z. Zuo. Position preference on glucuronidation of mono-hydroxyflavones in human intestine. Life Sci. 78:2772-2780 (2006).
23. J. Xing, X. Y. Chen, S. Q. Zhang, and D. F. Zhong. LC/MS analysis of baicalin and its isomer in rats urine J. Chinese Mass Spec. Soc. 25:129-133 (2004).
24. R. Muto, T. Motozuka, M. Nakano, Y. Tatsumi, F. Sakamoto, and N. Kosaka. The chemical structure of new substance as the metabolite of baicalin and time profiles for the plasma concentration after oral administration of Sho-Saiko-To in human Yakugaku Zasshi 118:79-87 (1998).
25. J.W. Bridges and L.F. Chasseaud. Progress in Drug metabolism vol. 8, Taylor & Francis, London, 1984 (chapter 2, pp. 53-54).